Insomnia is a common sleep disorder involving persistent difficulty falling asleep, staying asleep, or getting quality sleep despite enough opportunity. It can be acute or chronic and may lead to daytime fatigue, mood changes, and reduced cognitive performance.
FDA approved Orzeyful (oveporexton), the first drug to target the underlying loss of orexin signaling in narcolepsy type 1. In two 12-week trials, the twice-daily tablet improved wakefulness and reduced cataplexy versus placebo.
Two new surveys reveal that 24% of U.S. workers stay in unwanted jobs for health insurance, while 19% of adults with tinnitus have cut hours or quit. Debt and chronic illness increase job lock risk; cognitive behavioral therapy shows promise for tinnitus-related work impact.
University of Florida researchers have established AI Replacement Dysfunction (AIRD), a new clinical model for recognizing and treating stress from AI-driven job insecurity. The framework, published in Cureus, outlines symptoms including anxiety, insomnia, and loss of identity, and proposes screening and treatment approaches for affected workers.
A review of ClinicalTrials.gov registrations found few late-stage trials with robust sleep outcome measures in elderly Parkinson's disease patients. The analysis in BMC Geriatrics highlights outcome measure heterogeneity, underrepresentation of older adults, and short study durations as key gaps.
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
Clinical trials show psychedelic substances like psilocybin, LSD and MDMA combined with therapy can effectively treat depression, anxiety and addiction. Several substances are in Phase III trials, with esketamine already approved for treatment-resistant depression. Research suggests these treatments may work with fewer doses than traditional medications.
GSK agreed to license linerixibat to Alfasigma in a deal worth up to $690 million, while Eisai received orphan drug designation in Japan for E2086, a novel selective orexin 2 receptor agonist for narcolepsy.
The FDA approved pitolisant (Wakix) for treating cataplexy in children ages 6 and older with narcolepsy, making it the first non-scheduled treatment for both pediatric and adult narcolepsy patients with or without cataplexy.
The FDA has expanded approval of Wakix (pitolisant) to treat cataplexy in pediatric patients aged 6 years and older with narcolepsy, making it the first non-controlled substance approved for both pediatric and adult narcolepsy patients with or without cataplexy.
The FDA has approved Harmony Biosciences' Wakix (pitolisant) for treating cataplexy in pediatric patients aged 6 years and older with narcolepsy, making it the first non-scheduled treatment for both pediatric and adult narcolepsy patients with or without cataplexy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779499 |
Group-Based Brief Behavioral Therapy for Insomnia for Patients With Chronic Mental Illness |
NOT_YET_RECRUITING | NA |
| NCT07769515 |
Efficacy of Internet-based Cognitive Behavioral Therapy for Insomnia in Patients With Tinnitus and Insomnia |
NOT_YET_RECRUITING | NA |
| NCT07767617 |
Efficacy of Cognitive Behavioural Therapy for Insomnia and Bright Light Therapy in Adolescents With ADHD, Insomnia, and Evening Chronotype |
NOT_YET_RECRUITING | NA |
| NCT07764107 |
Photobiomodulation for Reducing Sedative-Hypnotic Use:Clinical Trial of a Light-Therapy Device |
NOT_YET_RECRUITING | NA |
| NCT07760779 |
Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness |
NOT_YET_RECRUITING | NA |
| NCT07754981 |
Self-Help Booklets for Sleep in Adults With Pulmonary Hypertension |
NOT_YET_RECRUITING | NA |
| NCT07754383 |
Qing-Xin-Jiao-Tai Decoction for Insomnia Comorbid With Obesity Presenting With Heart-Kidney Non-interaction Syndrome |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07751458 |
The WISE Study (WhatsApp Intervention for Sleep in the Elderly) |
NOT_YET_RECRUITING | NA |
| NCT07746570 |
SU JOK THERAPY TO IMPROVE DYSPNEA AND INSOMNIA IN ASTHMA |
COMPLETED | NA |
| NCT07746011 |
A Clinical Trial to Evaluate the Effects of EMF Protection Devices on Sleep and Energy Levels |
COMPLETED | NA |
